ILUVIEN Phase 4 Trial Hits Both Primary Endpoints, 24-Month Data Show Durable Efficacy
ANIP is trading near its 52-week low of $69.58 (6.2% above the low).
Summary
ANI Pharmaceuticals presented positive 6-month and 24-month data from the SYNCHRONICITY Phase 4 trial of ILUVIEN (fluocinolone acetonide intravitreal implant) in chronic non-infectious uveitis affecting the posterior segment. The trial met both co-primary endpoints with statistical significance at 6 months: mean BCVA improved by +3.6 letters (p=0.0077) and mean CST decreased by 157.5 microns (p<0.0001). At 24 months, efficacy was maintained with BCVA +5.5 letters and CST -171.2 microns, and 79.6% of patients experienced no recurrence of inflammation. Safety was consistent with prior trials, with ocular hypertension in 6% and cataract in 5% of patients. This is the first presentation of these data and supports the expanded ILUVIEN label for chronic NIU-PS approved in 2025. The results strengthen the commercial case for ILUVIEN in a niche ophthalmology market, though the open-label, single-arm design limits comparative claims. The company's Cortrophin Gel guidance cut in August remains a separate overhang.
At the time of this announcement, ANIP was trading at $73.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $69.58 to $97.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.